Piramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The company plans strategic investments to enhance capabilities in various segments and is also focusing on reducing debt. Currently, CDMO contributes significantly to its revenue.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.